What question did this study set out to answer?

To synthesize evidence regarding venous thromboembolism risk associated with gender-affirming hormone therapy across longitudinal and perioperative clinical settings.

December 17, 2022Endocrine PracticeOpen Access

Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review

View Full Paper

Ask AI

Bookmark

Authors

RARenata Arrington‐Sanders NCNathan T. Connell DCDevin Coon

Discussion

Member takes

Overview

Review highlights venous thromboembolism risks in transgender individuals receiving hormone therapy, indicating tailored management can mitigate complications without withholding care.

Key Points

To synthesize evidence regarding venous thromboembolism risk associated with gender-affirming hormone therapy across longitudinal and perioperative clinical settings.
Reviewed observational and clinical literature regarding venous thromboembolism risk in cisgender and transgender individuals receiving hormone therapy.
Assessed the effects of hormone formulation, dosing, administration route, and surgical contexts on patient thromboembolic and bleeding risks.
Hormone formulation, dosing, and administration route affect thromboembolic risk, with transdermal estrogen exhibiting the lowest risk profile.
Current venous thromboembolism prediction tools do not account for hormone therapy, although standard bleeding and recurrence risk scores remain clinically useful.
Withholding gender-affirming hormone therapy can result in adverse physical and psychological consequences, favoring individualized anticoagulation and therapy maintenance over routine discontinuation.

Cite This Study

Arrington‐Sanders et al. (2022) studied this question.

synapsesocial.com/papers/6a6f6ca08031ec7bb1dbbde0 https://doi.org/10.1016/j.eprac.2022.12.008

View Full Paper

Ask AI

Bookmark

December 17, 2022Endocrine PracticeOpen Access

Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review

View Full Paper

Ask AI

Bookmark

Authors

RARenata Arrington‐Sanders NCNathan T. Connell DCDevin Coon

Discussion

Member takes

Overview

Review highlights venous thromboembolism risks in transgender individuals receiving hormone therapy, indicating tailored management can mitigate complications without withholding care.

Key Points

To synthesize evidence regarding venous thromboembolism risk associated with gender-affirming hormone therapy across longitudinal and perioperative clinical settings.
Reviewed observational and clinical literature regarding venous thromboembolism risk in cisgender and transgender individuals receiving hormone therapy.
Assessed the effects of hormone formulation, dosing, administration route, and surgical contexts on patient thromboembolic and bleeding risks.
Hormone formulation, dosing, and administration route affect thromboembolic risk, with transdermal estrogen exhibiting the lowest risk profile.
Current venous thromboembolism prediction tools do not account for hormone therapy, although standard bleeding and recurrence risk scores remain clinically useful.
Withholding gender-affirming hormone therapy can result in adverse physical and psychological consequences, favoring individualized anticoagulation and therapy maintenance over routine discontinuation.

Cite This Study

Arrington‐Sanders et al. (2022) studied this question.

synapsesocial.com/papers/6a6f6ca08031ec7bb1dbbde0 https://doi.org/10.1016/j.eprac.2022.12.008

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark